263 related articles for article (PubMed ID: 16229678)
1. The product: All intravenous immunoglobulins are not equivalent.
Siegel J
Pharmacotherapy; 2005 Nov; 25(11 Pt 2):78S-84S. PubMed ID: 16229678
[TBL] [Abstract][Full Text] [Related]
2. The patient: Emerging clinical applications of intravenous immunoglobulin.
Harvey RD
Pharmacotherapy; 2005 Nov; 25(11 Pt 2):85S-93S. PubMed ID: 16229679
[TBL] [Abstract][Full Text] [Related]
3. Availability of immune globulin intravenous for treatment of immune deficient patients--United States, 1997-1998.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 1999 Mar; 48(8):159-62. PubMed ID: 10079062
[TBL] [Abstract][Full Text] [Related]
4. Information for healthcare providers on general features of IGIV with emphasis on differences between commercially available products.
Gürcan HM; Keskin DB; Ahmed AR
Autoimmun Rev; 2010 Jun; 9(8):553-9. PubMed ID: 20346419
[TBL] [Abstract][Full Text] [Related]
5. The pocketbook: Pharmacoeconomic issues related to intravenous immunoglobulin therapy.
Mahadevia PJ
Pharmacotherapy; 2005 Nov; 25(11 Pt 2):94S-100S. PubMed ID: 16229680
[TBL] [Abstract][Full Text] [Related]
6. Safety considerations in IGIV utilization.
Siegel J
Int Immunopharmacol; 2006 Apr; 6(4):523-7. PubMed ID: 16504914
[TBL] [Abstract][Full Text] [Related]
7. Differences between IGIV products: impact on clinical outcome.
Gelfand EW
Int Immunopharmacol; 2006 Apr; 6(4):592-9. PubMed ID: 16504921
[TBL] [Abstract][Full Text] [Related]
8. A new liquid, intravenous immunoglobulin product (IGIV 10%) highly purified by a state-of-the-art process.
Teschner W; Butterweck HA; Auer W; Muchitsch EM; Weber A; Liu SL; Wah PS; Schwarz HP
Vox Sang; 2007 Jan; 92(1):42-55. PubMed ID: 17181590
[TBL] [Abstract][Full Text] [Related]
9. The new generation of liquid intravenous immunoglobulin formulations in patient care: a comparison of intravenous immunoglobulins.
Stein MR
Postgrad Med; 2010 Sep; 122(5):176-84. PubMed ID: 20861601
[TBL] [Abstract][Full Text] [Related]
10. Pharmacy considerations for the use of IGIV therapy.
Shah S
Am J Health Syst Pharm; 2005 Aug; 62(16 Suppl 3):S5-11. PubMed ID: 16100386
[TBL] [Abstract][Full Text] [Related]
11. Safety of IGIV therapy and infusion-related adverse events.
Ballow M
Immunol Res; 2007; 38(1-3):122-32. PubMed ID: 17917017
[TBL] [Abstract][Full Text] [Related]
12. Cost savings from intravenous immunoglobulin manufactured from chromotography/caprylate (IGIV-C) in persons with primary humoral immunodeficiency disorder.
Mahadevia PJ; Strell J; Kunaprayoon D; Gelfand E
Value Health; 2005; 8(4):488-94. PubMed ID: 16091026
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and safety of subcutaneous immune globulin (human), 10% caprylate/chromatography purified in patients with primary immunodeficiency disease.
Wasserman RL; Irani AM; Tracy J; Tsoukas C; Stark D; Levy R; Chen J; Sorrells S; Roberts R; Gupta S
Clin Exp Immunol; 2010 Sep; 161(3):518-26. PubMed ID: 20550549
[TBL] [Abstract][Full Text] [Related]
14. IGIV: contents, properties, and methods of industrial production--evolving closer to a more physiologic product.
Martin TD
Int Immunopharmacol; 2006 Apr; 6(4):517-22. PubMed ID: 16504913
[TBL] [Abstract][Full Text] [Related]
15. Complementary use of passive surveillance and Mini-Sentinel to better characterize hemolysis after immune globulin.
Winiecki S; Baer B; Chege W; Jankosky C; Mintz P; Baker M; Woodworth T; Nguyen M
Transfusion; 2015 Jul; 55 Suppl 2():S28-35. PubMed ID: 26174895
[TBL] [Abstract][Full Text] [Related]
16. A newer immunoglobulin intravenous (IGIV) - Gammagard liquid 10%: evaluation of efficacy, safety, tolerability and impact on patient care.
Shah SR
Expert Opin Biol Ther; 2008 Jun; 8(6):799-804. PubMed ID: 18476791
[TBL] [Abstract][Full Text] [Related]
17. [The new domestic immunoglobulin G gabriglobin in complex therapy of immunodeficiency states and infectious pathology].
Pas'ko VG; Latysheva TV; Nikiforov VV; Mostovskaia EV; Denisov AK; Kondrashin IuI
Voen Med Zh; 2006 Jul; 327(7):40-2. PubMed ID: 16977880
[No Abstract] [Full Text] [Related]
18. Immune globulin subcutaneous, human - klhw 20% for primary humoral immunodeficiency: an open-label, Phase III study.
Sleasman JW; Lumry WR; Hussain I; Wedner HJ; Harris JB; Courtney KL; Mondou E; Lin J; Stein MR
Immunotherapy; 2019 Nov; 11(16):1371-1386. PubMed ID: 31621458
[No Abstract] [Full Text] [Related]
19. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology.
Orange JS; Hossny EM; Weiler CR; Ballow M; Berger M; Bonilla FA; Buckley R; Chinen J; El-Gamal Y; Mazer BD; Nelson RP; Patel DD; Secord E; Sorensen RU; Wasserman RL; Cunningham-Rundles C;
J Allergy Clin Immunol; 2006 Apr; 117(4 Suppl):S525-53. PubMed ID: 16580469
[TBL] [Abstract][Full Text] [Related]
20. Giving intravenous immunoglobulin.
Scherf R; White-Reid K
RN; 2008 Jan; 71(1):29-34; quiz 35. PubMed ID: 18271361
[No Abstract] [Full Text] [Related]
[Next] [New Search]
